Cytokinetics, Inc. Annual Shareholder Meeting
May 13, 2020 10:30 AM PDT
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>
SOUTH SAN FRANCISCO, Calif. , July 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a Virtual Investor and Analyst Day on Wednesday, July 15, 2020 from 8:30 AM to 11:30 AM ET . Members of Cytokinetics’ senior management will be joined by
SOUTH SAN FRANCISCO, Calif. ,, June 08, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Goldman Sachs 41 st Annual Global Healthcare
SOUTH SAN FRANCISCO, Calif. , and WASHINGTON , May 27, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2020 ALS Roundtables and ALS Focus, a
Fast Track Designation Highlights the Urgent Need for New Heart Failure Treatment Options THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , May 8, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S.
